Damian J. McColl

3.3k total citations · 1 hit paper
34 papers, 2.6k citations indexed

About

Damian J. McColl is a scholar working on Infectious Diseases, Virology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Damian J. McColl has authored 34 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Infectious Diseases, 24 papers in Virology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Damian J. McColl's work include HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (24 papers) and HIV/AIDS Research and Interventions (15 papers). Damian J. McColl is often cited by papers focused on HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (24 papers) and HIV/AIDS Research and Interventions (15 papers). Damian J. McColl collaborates with scholars based in United States, Australia and United Kingdom. Damian J. McColl's co-authors include Andrew Cheng, Edwin DeJesus, José Ramón Arribas, Anton Pozniak, Jeffrey Enejosa, Rafael Campo, Joel E. Gallant, John J. Toole, Brian Gazzard and Robin F. Anders and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and SHILAP Revista de lepidopterología.

In The Last Decade

Damian J. McColl

34 papers receiving 2.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

2006 703 citations Joel E. Gallant, Edwin DeJesus et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Damian J. McColl United States	23	2.0k	1.6k	522	428	386	34	2.6k
Joris Hemelaar United Kingdom	19	1.4k 0.7×	1.3k 0.8×	575 1.1×	170 0.4×	665 1.7×	44	2.5k
Chris Verhofstede Belgium	31	1.8k 0.9×	1.9k 1.2×	260 0.5×	167 0.4×	600 1.6×	101	2.7k
Georgios Pollakis Netherlands	29	1.1k 0.6×	1.7k 1.1×	685 1.3×	111 0.3×	785 2.0×	95	2.9k
Elna van der Ryst United Kingdom	25	1.5k 0.8×	1.6k 1.0×	340 0.7×	180 0.4×	551 1.4×	58	2.6k
Salvatore T. Butera United States	29	1.2k 0.6×	1.9k 1.2×	588 1.1×	105 0.2×	782 2.0×	58	2.8k
Horacio Salomón Argentina	31	2.3k 1.2×	2.4k 1.5×	525 1.0×	119 0.3×	893 2.3×	128	3.5k
C. McLaren United States	26	1.4k 0.7×	1.1k 0.7×	330 0.6×	264 0.6×	1.6k 4.1×	69	2.9k
Jason A. Young United States	17	630 0.3×	522 0.3×	337 0.6×	115 0.3×	437 1.1×	26	1.4k
Bluma Brenner Canada	37	4.2k 2.1×	4.1k 2.6×	676 1.3×	133 0.3×	1.1k 2.8×	143	5.0k
Oren J. Cohen United States	27	1.4k 0.7×	2.5k 1.6×	438 0.8×	227 0.5×	897 2.3×	43	3.6k

Countries citing papers authored by Damian J. McColl

Since Specialization

Citations

This map shows the geographic impact of Damian J. McColl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damian J. McColl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damian J. McColl more than expected).

Fields of papers citing papers by Damian J. McColl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damian J. McColl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damian J. McColl. The network helps show where Damian J. McColl may publish in the future.

Co-authorship network of co-authors of Damian J. McColl

This figure shows the co-authorship network connecting the top 25 collaborators of Damian J. McColl. A scholar is included among the top collaborators of Damian J. McColl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damian J. McColl. Damian J. McColl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ys, Kim, Shinichi Oka, Ploenchan Chetchotisakd, et al.. (2019). Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. SHILAP Revista de lepidopterología. 20(3). 73–81. 9 indexed citations

Kulkarni, Rima, Michael E. Abram, Damian J. McColl, et al.. (2014). Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients. HIV Clinical Trials. 15(5). 218–230. 21 indexed citations

Gazzard, Brian, Pierre Marie Girard, Giovanni Di Perri, et al.. (2014). Long‐term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV‐1‐infected treatment‐naïve subjects ≥50 years. Journal of the International AIDS Society. 17(4S3). 19767–19767. 2 indexed citations

Weber, Jan, Dane Winner, Nicolas Margot, et al.. (2013). Resistance Mutations outside the Integrase Coding Region Have an Effect on Human Immunodeficiency Virus Replicative Fitness but Do Not Affect Its Susceptibility to Integrase Strand Transfer Inhibitors. PLoS ONE. 8(6). e65631–e65631. 9 indexed citations

McColl, Damian J., Nicolas Margot, Shanshan Chen, et al.. (2011). Reduced Emergence of the M184V/I Resistance Mutation When Antiretroviral-Naïve Subjects Use Emtricitabine Versus Lamivudine in Regimens Composed of Two NRTIs Plus the NNRTI Efavirenz. HIV Clinical Trials. 12(2). 61–70. 20 indexed citations

Goodman, Derrick, Yun Zhou, Nicolas Margot, et al.. (2010). Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS. 25(3). 325–333. 73 indexed citations

McColl, Damian J. & Xiao‐Wu Chen. (2009). Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy. Antiviral Research. 85(1). 101–118. 136 indexed citations

DeJesus, Edwin, Benjamin Young, Javier O Morales-Ramirez, et al.. (2009). Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(2). 163–174. 108 indexed citations

Margot, Nicolas, et al.. (2009). Development of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Naïve Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934. JAIDS Journal of Acquired Immune Deficiency Syndromes. 52(2). 209–221. 44 indexed citations

10.

Elion, Richard, Calvin Cohen, Douglas Ward, et al.. (2008). Evaluation of Efficacy, Safety, Pharmacokinetics, and Adherence in HIV-1—Infected, Antiretroviral-Naïve Patients Treated with Ritonavir-Boosted Atazanavir Plus Fixed-Dose Tenofovir DF/Emtricitabine Given Once Daily. HIV Clinical Trials. 9(4). 213–224. 22 indexed citations

11.

Pozniak, Anton, Joel E. Gallant, Edwin DeJesus, et al.. (2006). Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(5). 535–540. 184 indexed citations

12.

DeJesus, Edwin, Daniel Berger, Martin Markowitz, et al.. (2006). Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(1). 1–5. 223 indexed citations

13.

McColl, Damian J., Nicolas Margot, Michael Wulfsohn, et al.. (2004). Patterns of Resistance Emerging in HIV-1 From Antiretroviral-Experienced Patients Undergoing Intensification Therapy With Tenofovir Disoproxil Fumarate. JAIDS Journal of Acquired Immune Deficiency Syndromes. 37(3). 1340–1350. 40 indexed citations

14.

McColl, Damian J.. (2003). The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1. Journal of Antimicrobial Chemotherapy. 51(2). 219–223. 10 indexed citations

15.

McColl, Damian J., et al.. (1999). Structure-based design of an RNA-binding zinc finger. Proceedings of the National Academy of Sciences. 96(17). 9521–9526. 36 indexed citations

16.

McColl, Damian J. & Robin F. Anders. (1997). Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3)1Note: Nucleotide sequence data reported in this manuscript are available in the EMBL, GenBank™ and DDJB data bases under the accession numbers L07944, L28825, U08851 and U08852.1. Molecular and Biochemical Parasitology. 90(1). 21–31. 75 indexed citations

17.

Marshall, Vikki M., Michael Foley, Susan L. Cranmer, et al.. (1997). A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infection and Immunity. 65(11). 4460–4467. 99 indexed citations

18.

Qian, Yan, et al.. (1996). Nuclear Magnetic Resonance Solution Structure of the Human Hsp40 (HDJ-1) J-domain. Journal of Molecular Biology. 260(2). 224–235. 131 indexed citations

19.

Mulhern, Terrence D., Geoffrey J. Howlett, Gavin E. Reid, et al.. (1995). Solution structure of a polypeptide containing four heptad repeat units from a merozoite surface antigen of Plasmodium falciparum. Biochemistry. 34(11). 3479–3491. 27 indexed citations

20.

McColl, Damian J., Anabel Silva, Michael Foley, et al.. (1994). Molecular variation in a novel polymorphic antigen associated with Plasmodium falciparum merozoites. Molecular and Biochemical Parasitology. 68(1). 53–67. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact